D-amino acid prodrug restores muscle protein synthesis in sarcopenia models

Researchers reporting in Molecular Therapy have engineered a clever D-amino acid prodrug called DLMEH that reactivates muscle-building pathways in sarcopenia. The compound works by targeting Sestrin2, a cellular amino acid sensor, to activate mTORC1—the master regulator of protein synthesis. This is counterintuitive since rapamycin and other longevity interventions typically inhibit mTOR, but the key difference is tissue-specificity and context: skeletal muscle needs adequate mTORC1 activity to maintain mass, while excess mTORC1 in other tissues may accelerate aging. Sarcopenia affects up to 30% of people over 60 and drives frailty, falls, and loss of independence. Current interventions are limited to resistance exercise and basic protein supplementation with mixed results. DLMEH represents a more sophisticated nutritional approach that could complement exercise by specifically enhancing the muscle's anabolic response. The D-amino acid structure offers advantages in bioavailability and resistance to degradation compared to regular amino acids. While this study appears to be preclinical (animal models), the prodrug strategy is inherently more translatable than gene therapies or biologics, potentially enabling faster movement toward human testing for this widespread age-related condition.